
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Study of TRX-920 for Patients With Advanced Solid Tumors
Details : TRX-920 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 22, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Bora Pharmaceuticals Partners with TaiRx
Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 27, 2022
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Details : Opdivo (Nivolumab) is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Opdivo
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 25, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Foslinanib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients
Details : CVM-1118 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2020
Lead Product(s) : Foslinanib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Foslinanib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Details : CVM-1118 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2018
Lead Product(s) : Foslinanib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
Details : Sorafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 11, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Foslinanib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients
Details : TRX-818 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2016
Lead Product(s) : Foslinanib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Foslinanib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
Details : TRX-818 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 24, 2015
Lead Product(s) : Foslinanib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
